Genentech profit up on robust cancer drug sales
Singularity 20 company
Genentech Inc. (NYSE:DNA - news), the world's second largest biotechnology company, on Tuesday said first-quarter profit rose 48 percent on strong sales of cancer drugs Avastin and Herceptin, and it raised its earnings forecast for the full year.
Genentech profit up on robust cancer drug sales
Genentech Inc. (NYSE:DNA - news), the world's second largest biotechnology company, on Tuesday said first-quarter profit rose 48 percent on strong sales of cancer drugs Avastin and Herceptin, and it raised its earnings forecast for the full year.
Genentech profit up on robust cancer drug sales
posted by jonas at
Tuesday, April 11, 2006
0 Comments:
Post a Comment
<< Home